Literature DB >> 22315639

Visual loss from hyphema following intravitreal bevacizumab.

Ahmad M Mansour1.   

Abstract

Intravitreal injections are the most common ocular procedures in an ophthalmic practice. Despite their safety profiles, complications can happen such as visually threatening intraocular bleeding. We present a case of a 32-year-old woman with idiopathic retinal vasculitis (Eales' disease), rubeosis iridis, and visual loss in the left eye from cystoid macular oedema. The patient had prior vitrectomy and multiple subtenon injections of corticosteroids. She underwent injection of intravitreal bevacizumab. The patient rubbed her eyes and developed subtotal hyphema. She also subsequently developed a panic attack. The bleeding spontaneously resolved over several hours. In eyes needing intraocular injections, caution needs to be taken in patients with rubeosis iridis who have had prior vitrectomy and subtenon injections of corticosteroids, and they need to be instructed to avoid ocular rubbing.

Entities:  

Year:  2010        PMID: 22315639      PMCID: PMC3028416          DOI: 10.1136/bcr.12.2009.2520

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Corneal topography after ocular rubbing.

Authors:  Ahmad M Mansour; Randa S Haddad
Journal:  Cornea       Date:  2002-11       Impact factor: 2.651

2.  The use of 31-gauge needles and syringes for intraocular injections.

Authors:  J S Pulido; C M Pulido; S J Bakri; C A McCannel; J D Cameron
Journal:  Eye (Lond)       Date:  2006-07-14       Impact factor: 3.775

3.  Globe rupture as a complication of intravitreal injection of triamcinolone.

Authors:  T Ung; C P R Williams; C R Canning
Journal:  Eye (Lond)       Date:  2006-09-22       Impact factor: 3.775

4.  Reduction of pegaptanib loss during intravitreal delivery using an oblique injection technique.

Authors:  L Lopez-Guajardo; F G Del Valle; J P Moreno; M A Teus
Journal:  Eye (Lond)       Date:  2008-01-18       Impact factor: 3.775

5.  Wound dehiscence after penetrating keratoplasty: clinical characteristics of 51 cases treated at Bascom Palmer Eye Institute.

Authors:  Ann M Renucci; Fabiana Bogossian Marangon; William W Culbertson
Journal:  Cornea       Date:  2006-06       Impact factor: 2.651

6.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

7.  Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.

Authors:  Radhika Krishnan; Srinivas Goverdhan; Jonathan Lochhead
Journal:  Clin Exp Ophthalmol       Date:  2009-05       Impact factor: 4.207

8.  Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.

Authors:  Friederike Mackensen; Carsten Heinz; Matthias D Becker; Arnd Heiligenhaus
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

9.  Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).

Authors:  Focke Ziemssen; Christoph M Deuter; Nicole Stuebiger; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-12       Impact factor: 3.535

10.  Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia.

Authors:  Dimitrios Brouzas; Chryssanthi Koutsandrea; Marilita Moschos; Spiros Papadimitriou; Ioannis Ladas; Michael Apostolopoulos
Journal:  Clin Ophthalmol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.